NAGE Q2 2024 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+11.9% YoY

Gross Profit

$14M60.2% margin

Operating Income

-$256,000-1.1% margin

Net Income

-$15,000-0.1% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+2.6%

Cash Flow

Operating Cash Flow

-$264,000

Free Cash Flow

-$276,000

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$54M

Total Liabilities

$23M

Stockholders' Equity

$31M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$20M	+11.9%
Gross Profit	$14M	$12M	+10.8%
Operating Income	-$256,000	-$2M	+88.9%
Net Income	-$15,000	-$2M	+99.3%